Dr Allen's Device is the only safe treatment to reduce the size of an enlarged prostate gland due to benign prostatic hyperplasia (BPH), treating lower urinary tract symptoms (LUTS).
BPH is not cancer and primarily requires careful and safe treatment that does not interfere with men’s daily life. Men should note that BPH is diagnosed in about 50% of men over 50. The incidence of prostate enlargement increases with age, reaching 90 percent in men over 80.
The effectiveness and safety of Dr Allen’s Device for Prostate Treatment has been proven in the controlled clinical trials. According to a scientific article: “Innovative Thermobalancing therapy and Dr Allen's Device for the first time employ body energy to treat chronic prostatic diseases effectively”, published in the leading medical journal, this device reduces the abnormal size of the enlarged prostate without side effects.
Standard BPH treatments drugs and surgeries are risky
The standard treatment options for BPH are medications and surgery, which have serious side effects, including sexual and erectile dysfunction, impotence, and diabetes. These new health conditions can cause additional mental problems and depression.
A medical article published in September 2021, “The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction” states that most treatments for LUTS associated with BPH result in ejaculatory dysfunction (ED), manifest as anejaculation, decreased ejaculation, retrograde ejaculation, painful ejaculation or premature ejaculation, and male fertility.
After BPH surgery, patients attach great importance to maintaining their sexual function, which can be irreversibly impaired.
Out-of-hospital use of Dr Allen’s Device is side effects free
Dr Allen’s Device has been registered with the Medical Regulatory Healthcare Agency in Great Britain since 2010, as a class 1 medical device that cannot harm. So, its safety is confirmed over the decade. This exclusive device and Thermobalancing therapy received a patent issued by the US Patent and Trademark Office, confirming the uniqueness of this treatment for BPH.
The Aging Male journal published the article “Use of Thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology”, which explains that Dr Allen’s Device treats the cause of BPH by improving blood circulation in the affected prostate, reducing enlargement of the prostate and urinary symptoms dramatically.
Fine Treatment produces and distributes Dr Allen’s Device
Thermobalancing treatment is used by people at home for over ten years successfully. The use of Dr Allen’s Device at home is important as it protects men from visiting clinics and hospitals, which are the most dangerous place for contracting a coronavirus infection.
Fine Treatment https://finetreatment.com/ manufactures Dr Allen’s Devices in the United Kingdom and makes them available worldwide, with free international delivery. Thousands of Fine Treatment’s customers with LUTS due to BPH across 100 countries have already benefited from this powerful and safe Thermobalancing therapy without BPH drugs and surgeries.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes


Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts
Synlait Milk Denies Fonterra, a2 Milk Takeover Talks
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
Nvidia’s $500 Billion AI Infrastructure Push Wins Morgan Stanley Support
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



